What it does, reaction by reaction
Deoxyribonucleotide Formation (Ribonucleotide Reductase pathway and thymidylate synthesis) Nucleotide Metabolism · Cytosol
dCMP → dUMP
› Notes
dCMP deaminase catalyzes dCMP + H2O → dUMP + NH3. The enzyme provides a second dUMP source and uses allosteric control to coordinate dCTP and dTTP pools; dCTP generally activates and dTTP inhibits the enzyme.
Pyrimidine De Novo Synthesis (through to UMP, then CTP/dTMP) Nucleotide Metabolism · Cytosol (one mitochondrial step)
dCMP → dUMP (alternative route)
› Notes
dCMP deaminase catalyzes dCMP + H2O → dUMP + NH3. This allosterically regulated reaction provides another major dUMP source and contributes to balanced dCTP/dTTP pools.
Showing all 2 reactions.
What accelerates and inhibits it
Regulation is pathway-specific, so each context is listed separately
Deoxyribonucleotide Formation (Ribonucleotide Reductase pathway and thymidylate synthesis)
dCTP (allosteric activation)
dTTP (allosteric inhibition)
Cell-cycle-linked expression; no major direct endocrine allostery.
Recent literature
Europe PMC · fetched just now · sorted by publication date
-
1
Potentially Functional Variants of <i>DCTD</i> and <i>ENTPD2</i> in the Metabolism of Nucleotide Pathway Genes Predict Survival of HBV-Related Hepatocellular Carcinoma Patients.
Mao Y, Lin Q, Liu Y, Wei X, Zhou Z, Wen Q, Jiang Y, Chen P, Liang X, Wei Y, Wei Q, Zhou W, Yu H. · 2026-07-14
unreviewed -
2
From Pharmacodynamic Biomarker to Evaluating Treatment Response: Biomarkers in Primary Mitochondrial Diseases.
Stern S, Crisamore K, Patton J, Schuck R, Pacanowski M. · 2026-06-01
open access unreviewed -
3
Low-density lipoproteins in human serum competitively inhibit the binding and entry of vesicular stomatitis virus.
Vandergaast R, Johnson S, Ziegler C, Nenavath GN, Schnebeck L, Narjari R, Russell SJ. · 2026-03-19
open access unreviewed -
4
Characterization of blood serum and cell lines by an automated high-throughput well plate sampling system using laser ablation-rapid evaporative ionization mass spectrometry.
Horkovics-Kováts GS, Simon D, Schäffer R, Pap I, Nozari Z, König A, Decking-Paede S, Szand R, Molnár A, Schlo… · 2026-04-28
open access unreviewed -
5
Deep Prior Framework: integrating functional specificity with general plausibility for targeted protein evolution.
Zhang S, Qin Y, Zhu H, Meng F, Jia L, Zheng X. · 2026-05-01
open access unreviewed -
6
PEGylation strategies for enhanced nanoparticle delivery to tumor-associated immune cells.
Cahn D, Pal S, Stern A, Patel NL, Gower T, Kapnick SM, Jewell CM, Duncan GA, Wolf MT. · 2025-12-10
open access unreviewed -
7
Fenofibrate as an anti-cancer treatment: an in vitro study on glioblastoma cells at various oxygen levels and on normal astrocytes.
Chokry Y, Groo AC, Corvaisier S, Ben Hadj Hassen O, Blanchard I, Valable S, Malzert-Fréon A. · 2026-05-02
open access unreviewed -
8
Correction to "Perfluorinated Iridium Catalyst for Signal Amplification by Reversible Exchange Provides Metal-Free Aqueous Hyperpolarized [1-<sup>13</sup>C]-Pyruvate".
Ettedgui J, Blackman B, Raju N, Kotler SA, Chekmenev EY, Goodson BM, Merkle H, Woodroofe CC, LeClair CA, Kris… · 2026-04-28
open access unreviewed -
9
Catabolism of extracellular glutathione supplies cysteine to support tumours.
Hecht F, Zocchi M, Tuttle ET, Ward NP, Alimohammadi F, Khan AA, Gomes VC, Smith B, Twardowski JJ, Mills BN, W… · 2026-03-18
cited 3× open access unreviewed -
10
Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade.
Talty R, Brooks VT, McGeary MK, Milette S, Zheng S, Flem-Karlsen K, Daniels A, Deshmukh M, Park K, Caraccio W… · 2026-05-01
cited 1× unreviewed
External claims. These come from an index outside this database and are not checked against it. Treat them as leads.